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Objective: Compare in vitro and in vivo characteristics and clinical outcomes of brand and generic alendronate.
Research design and methods: Relevant search terms were input into Medline (“alendronate” AND “generic” up to
August 5, 2013) and any abstracts deemed possibly relevant selected for full paper review and abstraction.
Results: Multicentre, randomized, placebo-controlled Phase III clinical trials of substantial size and duration have
established the anti-fracture efficacy and safety of brand amino-bisphosphonates. For regulatory approval, generic
versions of brand drugs need to demonstrate bioequivalence in young, healthy volunteers and have similar
dissolution times. While the potency and amount of active drug within generic formulations must be identical to
the brand, differences are permitted in the excipients. Significant differences in tablet disintegration time among
different versions of generic and brand alendronate have been reported. Rapidly disintegrating alendronate pills
may increase oesophageal bioadhesion and adverse event risk. Oesophageal-bound alendronate or slow
disintegrating alendronate tablets may be made inert and ineffective by subsequently ingested food or drink.
Investigations have reported a lower persistence to therapy with generic brands of alendronate as compared to
brand bisphosphonates and patients switched from brand to generic alendronate have increased adverse event
rates and losses in bone mineral density.
Conclusion: Numerous differences exist between brand and generic alendronate including: disintegration time,
bioadhesion to the oesophagus, patient persistence to therapy, adverse event incidence, and maintenance of bone
mineral density. Generic forms of alendronate warrant closer clinical study before they are ascribed the clinical
effectiveness and tolerability of brand alendronate.
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Osteoporosis is a systemic disease typified by decreased
bone strength and a consequent increased risk of fragil-
ity fracture (2000). Fragility fractures are associated with
significant decrements in quality of life (Papaioannou
et al. 2008) and decreased survival (Ioannidis et al.
2009). Further, acute and chronic care for fragility frac-
tures place a substantial economic burden on health care
systems (Tarride et al. 2012), which will only increase
with the aging of the developed world’s population.
In light of the personal and societal costs of fragility frac-
ture, their prevention is paramount. Positive lifestyle habits,* Correspondence: jd.adachi@sympatico.ca
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in any medium, provided the original work is psuch as varied physical activity and adequate vitamin D
and calcium intakes, play an important role in the preven-
tion of osteoporosis (Papaioannou et al. 2010). However,
once an individual has been found to possess a high risk
for fracture (as assessed by a 10-yr fracture risk assessment
tool), the clinical focus shifts towards treatment, which in-
cludes reinforcing positive lifestyle habits, but also necessi-
tates the probable addition of pharmaceutical therapies to
minimize this risk (Papaioannou et al. 2010).
First-line therapy for the treatment of postmenopausal
osteoporosis includes alendronate and risedronate
(oral amino-bisphosphonates), zoledronic acid (intravenous
amino-bisphosphonate), subcutaneous denosumab (RANK
ligand inhibitor), raloxifene (selective estrogen receptor
modulator), estrogen (hormone therapy) and teriparatide (re-
combinant parathyroid hormone) (Papaioannou et al. 2010).n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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are the most widely used for the treatment of osteopor-
osis, demonstrating significant anti-fracture efficacy at
vertebral, non-vertebral and hip sites when taken with
concomitant calcium and vitamin D supplementation
(MacLean et al. 2008). Further, the safety and tolerability
of the amino-bisphosphonates has been demonstrated in
Phase III trials (Black et al. 1996; Cummings et al. 1998;
McClung et al. 2001; Harris et al. 1999; Black et al.
2007), with tens of thousands of women followed for a
minimum three years. Continued efficacy and safety
have been shown with alendronate out to ten years of
administration (Bone et al. 2004). Shortly after brand
alendronate was released to market, there were numer-
ous reports of gastrointestinal (GI) adverse events (AEs)
with daily oral administration, particularly in the esophagus
(Castell 1996; de Groen et al. 1996; Ettinger et al. 1998). As
a result of these reports, the alendronate tablet was
reformulated with a waxy coating to minimize contact with
the esophagus and strict dosing instructions were added to
the package insert to ensure that the risk of exposure of
alendronate to the esophageal mucosa was minimized.
These changes to formulation and dosing, as well as later
availability of weekly dosing, all but eliminated GI AEs with
alendronate usage.
Despite the availability of proven anti-fracture medica-
tions, many patients who should be provided appropriate
therapy do not receive it: the majority of women and men
who suffer fragility fractures remain undiagnosed (>65%)
and untreated (>70%) for osteoporosis (Giangregorio et al.
2006; Bessette et al. 2008). Of the relatively small propor-
tion of patients who receive appropriate osteoporosis
therapy, one of the most significant challenges is the ubi-
quitously poor adherence to therapy (Siris et al. 2009;
Imaz et al. 2009). Both compliance (patient administers
therapy at appropriate time and according to dosing
instructions) (Weycker et al. 2007) and persistence (how
long a patient remains on the therapy) (Sheehy et al.
2009a) are low for osteoporosis therapies, including the
oral bisphosphonates. The anti-fracture benefits of osteo-
porosis medications increase with increasing compliance
(non-linearly) (Siris et al. 2006; Gallagher et al. 2008;
Rabenda et al. 2008) and a minimum of six to twelve
months of persistence is required in order to obtain the
anti-fracture benefits of the amino-bisphosphonates (Black
et al. 1996; McClung et al. 2001; Harris et al. 1999; Black
et al. 2007). Since osteoporosis is asymptomatic until frac-
ture, satisfactory adherence to therapy is even more
difficult to obtain than with symptomatic diseases. The in-
cidence of side-effects during osteoporosis therapy is a
significant cause of non-adherence (Hansen et al. 2008;
Rossini et al. 2006; Strampel et al. 2007; Anastasilakis
et al. 2007) as patients may feel worse while taking therapy
than when not. With adherence to therapy beingdisappointingly low with osteoporosis medications, the pa-
tient should be provided with a therapy that will minimize
side-effects and maximize their ability to administer ther-
apy accurately, reliably and for an extended period of time
so that the anti-fracture benefits described in clinical trials
can be realized.
The costs of health care are ever-escalating and as a
consequence many public and private payees have man-
dated numerous measures to minimize expenditures. One
of the most commonly-mandated cost-saving measures
has been to enforce a program of systematic generic
substitution for brand drugs after brand the patent has
expired (Lai et al. 2012; Grima et al. 2010). The belief is
that with this therapeutic substitution the patient will
receive the same therapy, with all of its known benefits
and risks, but at a lower cost to the payee. One study
that followed a large cohort found that in the year 2008
81% of patients that started the year on brand
alendronate had switched to generic alendronate by the
end of the year (Yun et al. 2013).
Alendronate was the first commercially-marketed
amino-bisphosphonate for the treatment of osteoporosis
and, consequently, the first to lose its patent and be
provided to the market as a generic drug. Recently,
risedronate (5 mg/d and 35 mg/w doses) has also been
made available as a generic option in a number of coun-
tries around the world. After its introduction, generic
alendronate was widely adopted by public and private
payees owing to its lower price as compared to brand
alendronate.
This review has the objective of detailing all published
in vitro, in vivo, clinical outcome and database compari-
sons between brand and generic alendronate to establish
whether the adherence, tolerance and efficacy results
obtained from Phase III clinical trials with brand
alendronate can be reasonably ascribed to generic forms
of alendronate. Further, a review of the cost-effectiveness
data is made.
Methods
Medline was searched to identify potential papers for
inclusion for this review, keywords “alendronate” AND
“generic” with the limitations of papers published
between January 1, 1995 and Aug 5, 2013 published in
English (n = 51 papers). After reviewing each reference’s
title and abstract, all papers that were deemed possibly
relevant to the topic were retained and had the full
paper acquired (n = 32). Reasons for non-inclusion (19)
were: non-english language (1), review (5), commentary
(3), not primary focus (6) and position statements (4).
Reference lists from acquired papers were scanned for
possible new citations. Numerous papers not gathered
from the search were included to provide perspective to
the discussion.
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When a patient chooses generic alendronate, or has
it chosen for them through mandatory substitution
(Strom & Landfeldt 2012), there is an underlying as-
sumption that the tolerability, safety and effectiveness
of the generic version of alendronate are equal to that
of brand alendronate.
Several federal guidelines exist to provide direction to
companies that manufacture and market generic ver-
sions of a branded drug (Federal Drug Administration
2008; Health Canada 1997). Generic versions must con-
tain identical amounts of the active ingredient(s) in an
identical dose formulation and the same route of admin-
istration as the brand and must adhere to rigid guide-
lines with respect to allowable limits for active drug
strength, purity and quality. However, variations between
the brand and generic version in the inactive ingredients
(excipients), such as binders, fillers and disintegrants,
are permitted so long as the excipients exist in a similar
ratio to that of the excipients in the brand formulation
(Meredith 2003).
Differences in excipient composition and behaviour
may result in altered disintegration or dissolution times
which could, in turn, change the bioavailability, pharma-
cokinetics and tolerability of the active drug. If differ-
ences in generic tablet composition exist, the tolerability,
safety and efficacy of a brand therapy reported from
clinical trials should not be automatically ascribed to the
generic version of a drug until otherwise confirmed by
assessing the generic in similarly designed randomized
control trials. Unfortunately, these confirmatory trials
are rarely, if ever, performed before regulatory permis-
sions are given for the marketing and sale of generics.
Bioavailability
Bioavailability is the degree of activity or the amount of
an administered drug or other substance that is made
available for action on the target cells. Changing a drug’s
bioavailability can lead to alterations in its safety and/or
efficacy profiles. The bioavailability of alendronate is ex-
ceedingly low (0.64%) when given on an empty stomach
to healthy, young volunteers under ideal circumstances
(Prescribing information 2010). If alendronate is taken
with food or liquids other than water it is made unavail-
able to the body due to binding with the food or drink
and passing through the digestive tract unabsorbed
(Porras et al. 1999). Consequently, it is recommended
that the drug be taken first thing in the morning with
water before ingesting any food or beverages with subse-
quent food and beverages withheld for at least 30
minutes following the administration of alendronate.
Further, the patient should remain upright for at least 30
minutes after ingestion to minimize the risk of GI reflux
and oesophageal irritation (Perkins et al. 2008).Differences in the excipient composition between the
brand and generic formulations of alendronate may alter
the bioavailability of the generic alendronate to bone if this
substitution changes the behaviour of the tablet such that
the alendronate tablet becomes more easily bound to food
or drink and unavailable for absorption in the gut.
Bioequivalence
Bioequivalence is defined by the Federal Drug Administra-
tion of the United States as “the absence of a significant
difference in the rate and extent to which the active ingre-
dient or moiety in pharmaceutical equivalents or pharma-
ceutical alternatives becomes available at the site of drug
action when they are administered at the same molar dos-
age under similar conditions in an appropriately designed
study” (Federal Drug Administration 2003).
Generic versions of alendronate have been reported to be
bioequivalent to branded alendronate (Rhim et al. 2009;
Yun et al. 2006; Lainesse et al. 2004). The development of a
brand name formulation requires the demonstration of its
pharmacokinetics, efficacy and tolerability in both healthy
subjects and in the target patient population. However, the
development of the generic equivalent requires only the
demonstration of its bioequivalence with the brand name
product in healthy subjects (Dighe 1999). The World
Health Organization guidelines state that 18 to 24 healthy
male and female volunteers aged 18 to 55 years of normal
body weight should be used in a crossover study design to
determine whether bioequivalence is achieved between two
formulations (World Health Organization 1996). It is as-
sumed that bioequivalence demonstrated in crossover stud-
ies performed in this typically younger, healthier population
would be equivalent to that observed in the patient popula-
tion. It is further supposed that this bioequivalence would
translate into comparable clinical efficacy and tolerance;
however, evidence to support the existence of a well-
defined relationship between these parameters is lacking
(Meredith 2003). These differences have fostered concern
as to whether bioequivalence, as ascertained in crossover
studies of healthy adults, should be used to make claims of
comparable clinical effectiveness and tolerability in patients
who are older and often have numerous underlying disor-
ders or diseases. Further, older individuals tend to have
greater difficulty in swallowing pills (orientation of pill in
mouth) and have reduced GI motility as compared to youn-
ger individuals. These differences may increase the expos-
ure time of the alendronate tablet to the upper GI tract
which could then increase the probability of alendronate
exposure to the esophagus in older adults.
In vitro and in vivo comparisons of brand and generic
alendronate
A number of in vitro investigations have compared per-
tinent physical characteristics of generic alendronate
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able differences.
In vitro: disintegration and dissolution
Since the bioavailability of alendronate is low and the
dosing requirements strict, any characteristics of tablets
that change the speed of delivery of alendronate, such as
time required for disintegration or dissolution, could
have important implications on drug effectiveness or tol-
erance. For regulatory approval, there are explicit dissol-
ution parameters required to allow for the generic
substitution of brand alendronate, however there are no
specifications as to the required disintegration character-
istics of the generic forms.
Disintegration is the physical process where the tablet
breaks down into fine particles. It is monitored visually
and relates to the physical integrity of the tablet. It is im-
portant to note that disintegration assays are not suffi-
cient to establish absorption rates – disintegration is the
initial step in drug release and its determination is im-
portant as a potential limiting factor in overall drug re-
lease (Bolanos 2004). Dissolution is the process by which
the active ingredient is dissolved into the liquid assay
medium. Dissolution is assessed via chemical analysis
and provides the approximate time required for full
solubilisation of the drug under test conditions.
With rapid drug disintegration there is a greater
chance of adhesion of the tablet to the oesophageal mu-
cosa, thereby increasing the risk of irritation and ulcer-
ation. Further, rapidly-disintegrating alendronate that is
adhered to the oesophagus may subsequently become
inert after contact with food or drink. In contrast, very
slow disintegration may increase the probability of the
drug coming into contact with subsequently ingested
food of drink, binding the alendronate and negating any
possible positive anti-fracture benefit.
Table 1 presents disintegration comparisons of brand
and generic forms of alendronate from all available trials.
Epstein et al. (2003) compared the disintegration profile
of brand alendronate with that of 13 generic versions of
alendronate available in Latin America. There were a
large number of generic versions of alendronate that
disintegrated faster than brand alendronate (brand
alendronate mean disintegration time of 1.4 minutes;
generic mean disintegration times ranging from 6.9 to 46.5
seconds) and generic versions that took far longer than
brand alendronate to disintegrate (mean disintegration
time ranging from 10.3 to 46.5 minutes).
In a study by Dansereau et al. (2008), the dissolution
and disintegration of a number of generic formulations of
alendronate from Canada, the Netherlands, Germany, and
the United Kingdom, were compared to United States-
manufactured brand risedronate and alendronate. All of
the generics tested had an acceptable dissolution rate ascompared to brand alendronate. Commercially-available
orally disintegrating tablets designed to dissolve in the
mouth without water prior to swallowing were purpose-
fully included to act as disintegration comparators. Six of
the 26 generic versions of alendronate tested had a disinte-
gration time that was comparable to that of the orally-
disintegrating tablets. Similarly, in a later study by
Dansereau et al. (2009), the majority of US-based generics
tested disintegrated rapidly enough to meet the regulatory
guidelines for an orally-disintegrating tablet.
In contrast to the above data, an investigation from
Portugal reported that there were no significant differ-
ences between the generic and brand alendronate formu-
lations for either dissolution or disintegration parameters
(Almeida et al. 2006). Another trial reported that brand
alendronate was more likely to cause GI injury than
generic versions since the generic brands released signifi-
cantly lower amounts of alendronate into solution than
the original product (Lamprecht 2009).
The majority of generic versions of alendronate disin-
tegrate faster or slower than brand alendronate, whereas
dissolution times are largely similar between brand and
generic alendronate.
In vivo: cleavage rupture and oesophageal adhesion
GI side effects are one of the most commonly reported
side effects associated with amino-bisphosphonates
(Black et al. 1996; Cummings et al. 1998; Ettinger et al.
1998). Alendronate-associated GI AEs have important
consequences, not only for patients’ health but also for
inducing GI-related direct and indirect medical costs
(Kane et al. 2004).
Pill-induced oesophagitis occurs primarily when the
ingested tablet adheres to the epithelial surface of the
oesophagus after swallowing and lesions develop. The
potential for developing pill-induced oesophagitis is
dependent on a number of factors including patient age-
related impairment of oesophageal motility, local pH,
the amount of water administrated with the pill, patient
position and formulation characteristics, including size,
shape and coating (Drake et al. 2002). Alendronate has a
high degree of oesophageal toxicity, owing to its very
low pH in aqueous solution (de Groen et al. 1996; Ep-
stein et al. 2005; Dobrucali et al. 2002) and if gastric acid
is refluxed after the administration of alendronate the
local damaging effect of alendronate may be enhanced
in this now lower pH environment (Dobrucali et al.
2002). It is recommended to take a full glass of water
after swallowing the alendronate pill to ensure that is
clears the oesophagus rapidly. Oesophageal irritation,
and even ulceration, have been reported in patients who
were non-complaint in the dosing instructions to take
the therapy with sufficient water and to avoid lying
down or being semi-supine for a period of half an hour
Table 1 Disintegration rates of brand alendronate and generic alendronate
Lead author, year Brand or generic Dose Trade or Manufacturer
name
Country
of origin
n Dsnt time
(s) (mean)
Dsnt time
(s) (sd)
% RSD Dsnt
< 30s
Epstein, 2003 Brand 70mg Fosamax, Merck & Co., Inc. US 27 86.1 11.8 14% N
Generic 70mg Fosval Chile 12 6.9 1.5 23% Y
Generic 70mg Osteoplus Ecuador 12 14.7 1.6 11% Y
Generic 70mg Fixopan Ecuador 14 16.2 2.1 13% Y
Generic 70mg Osteomix Ecuador 12 22.4 2.1 9% Y
Generic 70mg Genalmen Venezuela 8 26.1 1.9 7% Y
Generic 70mg Genalmen Venezuela 4 19.5 3.1 16% Y
Generic 70mg Endronax Brazil 12 32.8 4.7 15% N
Generic 70mg Osteomax Costa Rica 13 44.2 3.7 8% N
Generic 70mg Fosmin Peru 10 46.5 11.6 25% N
Generic 70mg Defixal Venezuela 12 46.5 4.4 10% N
Generic 70mg Ostenan Brazil 14 25.0 11.2 45% Y
Generic 70mg Regenesis Argentina 20 13.0 1.7 13% Y
Generic 70mg Neobon Columbia 23 13.0 6.7 52% Y
Dansereau, 2008 Brand 70mg Fosamax, Merck & Co., Inc. “A” US 4-6 43 11 26% N
Brand 70mg Fosamax, Merck & Co., Inc. “B” US 4-6 78 12 15% N
Brand 70mg Fosamax, Merck & Co., Inc. “C” US 4-6 52 23 44% N
Brand 35mg Actonel, P&G Pharmaceuticals “A” US 4-6 35 3 9% N
Brand 35mg Actonel, P&G Pharmaceuticals “B” US 4-6 44 7 16% N
Brand 35mg Actonel, P&G Pharmaceuticals “C” US 4-6 49 6 12% N
Generic 70mg Apotex “A” Canada 4-6 198 78 39% N
Generic 70mg Apotex “B” Canada 4-6 132 48 36% N
Generic 70mg Apotex “C” Canada 4-6 192 48 25% N
Generic 70mg Cobalt “A” Canada 4-6 150 42 28% N
Generic 70mg Cobalt “B” Canada 4-6 174 48 28% N
Generic 70mg Novopharm “A” Canada 4-6 21 7 33% Y
Generic 70mg Novopharm “B” Canada 4-6 13 1 8% Y
Generic 70mg Novopharm “C” Canada 4-6 24 50 208% Y
Generic 70mg Pharmascience Canada 4-6 126 48 38% N
Dansereau, 2009 Brand 70mg Fosamax, Merck & Co., Inc. US 6 53 9 17% N
Generic 70mg Teva Pharma “A” US 6 60 24 40% N
Generic 70mg Teva Pharma “B” US 6 27 3 11% Y
Generic 70mg Teva Pharma “C” US 6 72 6 8% N
Generic* 70mg Watson Pharma US 6 108 42 39% N
Generic 70mg Barr Laboratories, Inc “A” US 6 10 2 20% Y
Generic 70mg Barr Laboratories, Inc “B” US 6 9 1 11% Y
Generic 70mg Barr Laboratories, Inc “C” US 6 9 2 22% Y
Generic 70mg Aluid Germany 4-6 84 18 21% N
Generic 70mg AWD Germany 4-6 168 18 11% N
Generic 70mg Betapharm “A” Germany 4-6 342 96 28% N
Generic 70mg Betapharm “B” Germany 4-6 156 42 27% N
Generic 70mg Betapharm “C” Germany 4-6 174 48 28% N
Generic 70mg GRY Germany 4-6 21 5 24% Y
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Table 1 Disintegration rates of brand alendronate and generic alendronate (Continued)
Generic 70mg Hexal “A” Germany 4-6 336 66 20% N
Generic 70mg Hexal “B” Germany 4-6 60 6 10% N
Generic 70mg Hexal “C” Germany 4-6 150 54 36% N
Generic 70mg Heuman Germany 4-6 168 24 14% N
Generic 70mg Juta Germany 4-6 30 4 13% N
Brand 70mg Fosamax, Merck & Co., Inc. Germany 4-6 84 18 21% N
Generic 70mg Ratiopharm “A” Germany 4-6 84 24 29% N
Generic 70mg Ratiopharm “B” Germany 4-6 246 42 17% N
Generic 70mg Ratiopharm “C” Germany 4-6 198 36 18% N
Generic 70mg Stada “A” Germany 4-6 186 84 45% N
Generic 70mg Stada “B” Germany 4-6 186 96 52% N
Generic 70mg Stada “C” Germany 4-6 222 24 11% N
Generic 70mg Apothecon Netherlands 4-6 106 30 28% N
Generic 70mg Kromme Netherlands 4-6 58 14 24% N
Generic 70mg Centrapharm Netherlands 4-6 330 60 18% N
Generic 70mg Pharmachemie Netherlands 4-6 14 4 29% Y
Generic 70mg Ratiopharm Netherlands 4-6 66 18 27% N
Generic 70mg Sandoz Netherlands 4-6 72 30 42% N
Generic 70mg APS/Teva “A” UK 4-6 37 9 24% N
Generic 70mg APS/Teva “B” UK 4-6 26 5 19% Y
Generic 70mg Arrow “A” UK 4-6 144 60 42% N
Generic 70mg Arrow “B” UK 4-6 34 9 26% N
Generic 70mg Pliva UK 4-6 60 12 20% N
Generic 70mg Ratiopharm UK 4-6 78 18 23% N
Generic 70mg Teva “A” UK 4-6 14 3 21% Y
Generic 70mg Teva “B” UK 4-6 29 5 17% Y
Generic 70mg Winthrop “A” UK 4-6 132 36 27% N
Generic 70mg Winthrop “B” UK 4-6 306 36 12% N
*manufactured by Merck, sold by Watson Pharma Inc.
%RSD = relative percent standard deviation; n = number of tablets tested; Dsnt = disintegration in seconds.
Brown et al. SpringerPlus 2013, 2:550 Page 6 of 12
http://www.springerplus.com/content/2/1/550after administration (Castell 1996; de Groen et al. 1996;
Strampel et al. 2007; Naylor & Davies 1996). However,
there have been reports of oesophageal irritation even in
those who claim compliance to the dosing instructions.
Further, clinical concentrations of both alendronate
and risedronate have been demonstrated to suppress
the growth of epidermal keratinocytes through the
same mechanisms that are integral in their control of
osteoclast activity – inhibition of farnesyl diphosphate
synthase (Reszka et al. 2001). A few trials have sug-
gested that the combination of alendronate and non-
steroidal anti-inflammatory medications may have a
synergistic ulcerogenic effect (Ettinger et al. 1998; Graham
& Malaty 2001).
A number of investigations have studied the impact of
different excipients on the rupture characteristics betweengeneric and brand alendronate tablets and whether this
plays a role in oesophageal adhesion.
If the alendronate tablet is ingested with little or no
water it can come into direct contact with the oesophageal
epithelium and can even become compressed against the
esophagus during the contraction phase of peristalsis
during swallowing (Dai et al. 2003; Mittal et al. 2005).
It is possible during this compression and in the ab-
sence of sufficient water for bioadhesion forces created
from the solid form to be greater than the detachment
forces produced from drinking liquids or from subse-
quent peristaltic movements.
Shakweh et al. (2007) investigated the bioadhesive
characteristics of generic alendronate manufactured in
Europe and brand alendronate, along with one negative
and two positive polymer controls, in a porcine oesophageal
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characteristics whereas the generic tablets made by Teva
had bioadhesive characteristics that were similar to the
positive control. Several other forms of generic tablets
(Alenat, Stada, Aliud, Ratiopharm) displayed cleavage rup-
ture in the oesophagus leaving a large piece of tablet
strongly adhering to the mucosa. The brand alendronate
studied did not demonstrate this rupturing behaviour. In
cleavage rupture the adhesive forces from the mucosa
were greater than that of the tablet cohesiveness. It is
possible in this circumstance that drinking sufficient
water when taking the tablet would force it down the
oesophagus without adhesion to the oesophageal wall.
However, if insufficient water was consumed or the
adhesive strength was too great, adhesion may occur
resulting in irritation of the mucosa. It was hypothesized
that the differences in bioadhesion and cleavage rupture
were likely due to differing inactive ingredients.
Perkins et al. (2008) assessed the oesophageal transit
time of branded risedronate and two generic alendronate
formulations. It was found that a semi-sitting posture, as
opposed to being upright, significantly (p < 0.05) slowed
oesophageal transit time. Further, the generic alendronate
formulations had significantly (p < 0.01) slower transit
times than the risedronate tablets. Further, rupture of gen-
eric alendronate tablets was noted in some of the trials, in
both the upright and semi-supine positions. Slower transit
times in combination with rapid disintegration of generic
tablets could greatly increase the likelihood of mucosa ad-
hesion and exposure.
Epstein et al. (2005) used a canine model to assess dif-
ferences in oesophageal tolerability between brand and
generic alendronate. In the study the dogs were exposed
to generic or brand alendronate on the caudal third of
the oesophagus for one hour in each of five consecutive
days (saline rinse after each application). All four of the
dogs that were exposed to the generic alendronate
exhibited marked ulcerative oesophagitis whereas it only
developed in one for five of the dogs that were exposed
to brand alendronate.
In conclusion, laboratory data demonstrates that there
are frequent differences between brand and generic
alendronate in GI transit time, in bioadhesion to the
oesophagus and in the propensity for tablet rupture.
Clinical data
In clinical trials, brand alendronate has similar safety
and tolerability profiles as compared to placebo (Black
et al. 1996; Cummings et al. 1998; Liberman et al. 1995;
Devogelaer et al. 1996; Tonino et al. 2000; Schnitzer
et al. 2000; Rizzoli et al. 2002). Therefore, any differences
in tolerability in the real world could potentially be due
to either improper dosing or to the different formula-
tions of alendronate.When investigating whether there are differences in safety
or effectiveness between generic versions of alendronate
and the brand version, a common approach is to assess
experiences in clinical populations outside of the trial
setting. Chart reviews of community-based patients can
provide real-world data comparing important outcomes
with respect to tolerance and effectiveness of brand
and generic versions of alendronate.
In a Canadian study, a chart review of 301 women
from two specialized tertiary care referral centers was
undertaken to quantify changes in AE rates, changes in
bone mineral density, and discontinuation among post-
menopausal women greater than 50 years of age before
and after switching from brand to generic alendronate
(Grima et al. 2010). Patients who were previously stable
on doses of brand alendronate experienced an increase
in AEs which were serious enough to result in discon-
tinuation after introduction of automatic substitution
to generic alendronate. In addition, reductions in bone
mineral density were observed in some patients who
had stable bone mineral density while on brand
alendronate (prior to January 2005). Given the substan-
tial increase in AEs recorded after the automatic substi-
tution of brand alendronate by generic alendronate it
could be suggested that generic alendronate may not be
as well tolerated as brand alendronate.
In another chart review, this time of a German prac-
tice, Ringe and Moller (2009) reported differences in
persistence, safety and effectiveness in 186 postmeno-
pausal women with osteoporosis treated with brand
alendronate, brand risedronate or generic alendronate
over a period of a year. After a year of therapy, the mean
increases in bone mineral density at both the lumbar
spine and total hip were significantly lower (p < 0.05) for
the generic alendronate group as compared to either of
the groups of women provided brand bisphosphonates.
After a year, only 68% of the patients taking generic
alendronate were persistent with therapy, as compared
to 84% of the patients taking brand alendronate and 94% of
the patients taking brand risedronate (p < 0.05 between
generic vs either brand). Perhaps explaining the lower per-
sistence with generic alendronate was the significantly
(p < 0.05) higher rate of AEs in the women taking generic
alendronate (n = 32) as compared to those women taken
brand alendronate (n = 15) or brand risedronate (n = 9).
Lai et al. (2012) assessed the impact of mandatory gen-
eric alendronate substitution on adherence and adverse
event incidence. In this small investigation, there were
no significant differences between generic and brand
alendronate with respect to medication adherence, but
patients that were provided generic alendronate had a
significantly greater incidence of AEs as compared to
those women on the brand formulation (OR = 7.84; 95%
CI: 2.98, 20.65).
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generic alendronate is compared to brand alendronate
there are significant differences in persistence to therapy,
effectiveness (bone mineral density) and safety (AEs).
Database analyses
Another common approach to compare whether there
are differences in persistence, safety or effectiveness be-
tween generic versions of alendronate and the brand ver-
sion is to perform analyses of administrative databases.
In an administrative database analysis, information regard-
ing persistence to therapy of once-weekly bisphosphonates
was obtained from a large cohort of patients by linking
the administrative databases of the Régie de l’Assurance
Maladie du Québec (RAMQ) (Sheehy et al. 2009a). The
RAMQ database collects prescribing and prescription
filling information for all residents of the province of
Quebec, Canada who were not covered by private health
insurance (60% of residents aged 18–64 and almost
98% of 65 and older) (Régie de l'assurance maladie du
Québec 2010).
In this analysis, data was isolated for bisphosphonate-na
ïve patients who were started on brand risedronate
(13,441 patients), brand alendronate (18,488 patients), or
generic alendronate (875 patients) and the patients were
then followed forward in time for a year from their first
prescription. Patients who were initiated on weekly gen-
eric alendronate had a significantly (p < 0.0001) lower per-
sistence to therapy as compared to those patients who
began weekly brand risedronate or brand alendronate
therapy. Even after adjusting for confounding covariates
(female gender, socioeconomic status, previous osteopor-
otic fracture, number of family physician or specialist visits
in past year, number of days in hospital in the past year,
number of days in the ER in past year and chronic disease
score), patients initiated on weekly generic alendronate
had a significantly higher probability of discontinuing
therapy as compared to either brand risedronate or
alendronate (Hazard ratio = 2.08, 95% CI: 1.89-2.28). The
significant difference between persistence to the generic
versus the brand bisphosphonates may be attributable to
physiochemical differences between the formulations, or
to differences in the populations dispensed the drugs.
Another investigation using the same administrative
RAMQ databases as the study above concluded that
persistence to brand bisphosphonates was significantly
(p < 0.001) higher than to generic alendronate for patients
who either had (primary prevention) or had not (second-
ary prevention) previously experienced an osteoporotic
fracture (Sheehy et al. 2009b). Even after controlling for
numerous covariates there was significant risk for dis-
continuation with generic alendronate as compared to
brand alendronate (hazard ratio = 2.08, 95% confidence
interval 1.89–2.28).Strom and Landfeldt (2012) conducted an analysis of
data from a large Swedish database (Swedish Prescribed
Drug Registry) that contained information of prescrip-
tion dispensation from 2006 through 2009. They
reported that automatic generic substitution of generic
alendronate was associated with reduced treatment per-
sistence. From 2006 to the end of 2009 automatic substi-
tution of generic alendronate increased from 11% to 45%
with a concomitant decrease in one-year persistence to
therapy from 67% to 52%. Those patients that had their
alendronate substituted at their first prescription refill
had a significantly higher probability of discontinuing
their therapy (HR = 1.25; 95% CI: 1.2, 1.3).
In contrast to the above investigations, van Boven
et al. (2013) found that use of generic alendronate was
not associated with a decreased one-year persistence to
therapy as compared to other brand bisphosphonates.
Specifically, no difference was observed between the
branded and generic forms of alendronate (HR = 1.00;
95% CI: 0.89, 1.12).
In 2005, the patent for alendronate expired in the UK
and there was large-scale switching of bisphosphonate
users to the generic formulation of alendronate. Ralston
et al. (2010) conducted a database analysis (retrospective
cohort study) to investigate whether there was a differ-
ence in GI tract AEs between patients who were pro-
vided risedronate and remained on risedronate and
those who began on risedronate and switched to
alendronate after March 2005 (generic introduction).
The investigators found that there was an increased risk
of GI AEs for those patients switched from risedronate
to alendronate (HR = 1.85; CI: 1.26, 2.72), with a greater
risk in those with a history of GI events (HR = 3.18; 95%
CI: 2.79, 3.63).
In a retrospective database health resource utilization
analysis of upper GI tract outcomes in patients started on
either generic (from Israel) or brand alendronate, it was
concluded that there were significantly higher discontinu-
ation rates with the generic versions of alendronate as
compared to the brand alendronate (incident rate ratios
1.3-1.59; p < 0.05) (Halkin et al. 2007). However, in this in-
vestigation the authors found no difference between users
of brand and generic alendronate in the incidence of
upper GI AEs. Specifically, there were no differences
between brand and generic alendronate for visits to a
gastroenterologist (<1%), for GI-related hospitalizations
(2.9-3.2%) and for rates of new gastric drug therapy (3.5–
4.9%). Further, for those who required an endoscopy
investigations there were no differences in endoscopic diag-
noses among the formulations tested. Notably, the authors
excluded any patient with prior upper GI tract problems
or patients that discontinued in the first three months.
Different from the other investigations (Sheehy et al.
2009b; Blouin et al. 2009) was the fact that the database
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scription; it may be that the AEs associated with generic
versions of alendronate become more evident after this
time and were not yet clinically identifiable.
In another analysis of the Swedish registry data (2005
through 2009), Landfeldt & Strom (2012) reported that
there was no difference between branded and generic
alendronate when the rates of GI adverse events were
assessed within the first six months of alendronate pre-
scription. Similar to the study above, six months of obser-
vation may have been an insufficient period of time of
observation to detect GI adverse events. Further study of
additional large databases in this manner is warranted.
Cost-effectiveness
Since generic alendronate has commanded such a large
share of the osteoporosis treatment market in recent
years largely owing to its low cost, numerous cost-
effectiveness analyses have been conducted to compare
the cost of preventing fractures with generic alendronate
to other brand therapies, most often denosumab.
Nayak et al. (2012) used a Monte Carlo simulation
model to assess when osteoporosis screening with ap-
propriate treatment would become cost-effective in
women 65 years of age or older. Analyses revealed that
at prices below $200 per year, screening with appropriate
alendronate treatment resulted in significant cost-
savings (up to $343 per quality-adjusted life-year or
QALY). While costs for alendronate between US $400
and $800 we no longer cost-saving, they were still cost-
effective with incremental cost-effectiveness ratios
(ICERs) from US $714 to $13,902 per QALY gained.
In a comparison of the cost-effectiveness of denosumab
to bisphosphonates for the prevention of hip fracture, gen-
eric alendronate was used as the low-cost comparator
in postmenopausal women with varying fracture risk
(Parthan et al. 2013). In the general analysis of cost-
effectiveness with the overall postmenopausal population,
the use of denosumab was cost-effective, even when com-
pared to generic alendronate (ICER $US 85,100/QALY).
In the high risk subgroup consisting of women with two
or more risk factors for fracture, denosumab was compar-
able to generic alendronate with an ICER of $US 7,900/
QALY. Further, when the analysis was extended to women
75 years of age or older, denosumab was superior to gen-
eric alendronate and all other comparators. In an analysis
using a Markov simulation model, denosumab was found
to be a cost-effective replacement for generic alendronate
when the 10-year risk of major osteoporotic fracture was
32% or greater (Strom et al. 2013). Another Markov model
simulation of the cost-effectiveness of denosumab mod-
elled on Swedish data was completed by Jonsson et al.
(2011). Treatment with denosumab was more expensive
initially than all other therapies investigated, substantiallymore than generic alendronate. In this model, the ICER
for denosumab as compared to generic alendronate was
about Euro 27,000, but the marked discontinuation rates
associated with generic alendronate use offset many of the
gains of generic alendronate being low-cost. A similar in-
vestigation from Belgium concluded that denosumab was
cost-effective when compared to other bisphosphonates, in-
cluding generic alendronate, for the treatment of postmen-
opausal osteoporosis in women 60 years of age or older
with an osteoporotic bone mineral density or with a preva-
lent vertebral fracture over a three year period (Hiligsmann
& Reginster 2011). One assumption made in this analysis,
however, was that the persistence to denosumab would be
46% higher than to the oral bisphosphonates.
The cost-effectiveness studies have shown that generic
alendronate, while being the least expensive alternative for
the treatment of osteoporosis, can often be supplanted by
other therapies as a first choice when long-term costs are
considered, particularly when assessing the high rates of
discontinuation assumed for generic alendronate in many
of these models.
Of note, in many countries the manufacturer of brand
alendronate substantially lowered their pricing of brand
alendronate, now combined with vitamin D, to be simi-
lar to that of generic alendronate. This relatively recent
change requires for new cost-effectiveness studies to be
completed with the newer formulation of alendronate
and vitamin D with the new pricing.
Conclusion
Alendronate continues to play an important role in the
management of osteoporosis. The proliferation of generic
versions of brand alendronate has been rapid worldwide.
Brand alendronate has undergone years of carefully moni-
tored randomized placebo-controlled clinical trials, utilizing
tens of thousands of osteoporosis patients, to establish tol-
erability, safety and efficacy. Further, numerous Phase IV
investigations have supported the findings reported in
Phase III clinical trials. The generic versions of alendronate
have not been tested with the same rigour for tolerance,
safety and efficacy.
Differences in excipients may be an important factor in
the frequently reported differences in disintegration time
between generic and brand alendronate. Most commonly,
generic versions disintegrate far more rapidly than brand
alendronate, increasing the potential for AEs. Differences
in rupture characteristics of generic and brand alendronate
may also increase the probability of oesophageal damage
with the generic versions of alendronate.
Lastly, clinical data has consistently demonstrated that
tolerance and effectiveness of generic alendronate is
lower than that of the brand versions.
While generic substitutions may lead to equivalent
outcomes to the brand formulation in other drug
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the case with alendronate; the efficacy, effectiveness
and tolerance ascribed to brand alendronate should not
be extrapolated to the relatively untested generic ver-
sions of alendronate.
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